Cargando…

A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease

AIMS: Objective methods to monitor statin adherence are needed. We have established a liquid chromatography–tandem mass spectrometry assay for quantification of atorvastatin and its metabolites in blood. This study aimed to develop an objective drug exposure variable with cut‐off values to discrimin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kristiansen, Oscar, Vethe, Nils T., Fagerland, Morten W., Bergan, Stein, Munkhaugen, John, Husebye, Einar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955401/ https://www.ncbi.nlm.nih.gov/pubmed/31495943 http://dx.doi.org/10.1111/bcp.14122

Ejemplares similares

Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
por: Kristiansen, Oscar, et al.
Publicado: (2020)

Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects
por: Peersen, Kari, et al.
Publicado: (2021)

Plasma concentration of atorvastatin metabolites correlates with low‐density lipoprotein cholesterol reduction in patients with coronary heart disease
por: Sverre, E., et al.
Publicado: (2023)

Medical and sociodemographic factors predict persistent smoking after coronary events
por: Sverre, Elise, et al.
Publicado: (2017)

Unfavourable risk factor control after coronary events in routine clinical practice
por: Sverre, Elise, et al.
Publicado: (2017)

Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients—A Cross-Validation Study
por: Kindem, Ingvild Andrea, et al.
Publicado: (2021)

Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
por: Kloster-Jensen, Kristine, et al.
Publicado: (2016)

Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation
por: Klaasen, Rolf Anton, et al.
Publicado: (2020)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study
por: Bremer, Sara, et al.
Publicado: (2009)

Managing patients with prediabetes and type 2 diabetes after coronary events: individual tailoring needed - a cross-sectional study
por: Munkhaugen, John, et al.
Publicado: (2018)

Validated spectrofluorimetric method for the determination of atorvastatin in pharmaceutical preparations
por: Sharaf El-Din, Mohie M.K., et al.
Publicado: (2012)

Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy
por: Tsioufis, Konstantinos, et al.
Publicado: (2021)

Fasting Status and Circadian Variation Must be Considered When Performing AUC‐based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
por: Gustavsen, Marte Theie, et al.
Publicado: (2020)

Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease
por: Xu, Danyan, et al.
Publicado: (2017)

Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease
por: Li, Tao, et al.
Publicado: (2018)

Spectrophotometric and TLC-densitometric methods for the simultaneous determination of Ezetimibe and Atorvastatin calcium
por: Baghdady, Yehia Z., et al.
Publicado: (2013)

Validated spectrophotometric methods for the simultaneous determination of telmisartan and atorvastatin in bulk and tablets
por: Ilango, Kaliappan, et al.
Publicado: (2012)

The Attention Training Technique Reduces Anxiety and Depression in Patients With Coronary Heart Disease: A Pilot Feasibility Study
por: Dammen, Toril, et al.
Publicado: (2022)

Predictors of health-related quality of life in outpatients with coronary heart disease
por: Frøjd, Lars Aastebøl, et al.
Publicado: (2023)

Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population
por: Sverre, E., et al.
Publicado: (2020)

Tongxinluo Capsule Combined with Atorvastatin for Coronary Heart Disease: A Systematic Review and Meta-Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Parametric methods outperformed non-parametric methods in comparisons of discrete numerical variables
por: Fagerland, Morten W, et al.
Publicado: (2011)

A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
por: Karvaly, Gellért Balázs, et al.
Publicado: (2021)

Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome
por: Liu, Zhi, et al.
Publicado: (2017)

Relationships between depression, anxiety, type D personality, and worry and rumination in patients with coronary heart disease
por: Tunheim, Kristoffer, et al.
Publicado: (2022)

Effect of CETP Polymorphism on Atorvastatin Lipid-Regulating Effect and Clinical Prognosis of Patients with Coronary Heart Disease
por: Gu, Guo-Long, et al.
Publicado: (2014)

Inflammatory cell infiltrates in the heart of patients with coronary artery disease with and without inflammatory rheumatic disease: a biopsy study
por: Andersen, Jacqueline K., et al.
Publicado: (2016)

Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
por: Niu, Hongmei, et al.
Publicado: (2018)

Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease
por: Frøjd, Lars Aastebøl, et al.
Publicado: (2022)

Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen
por: Patel, Bimal V, et al.
Publicado: (2008)

Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial
por: Goswami, Nilesh J, et al.
Publicado: (2013)

Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method
por: Pusapati, Ravi Teja, et al.
Publicado: (2014)

Cardioprotective Effects of Atorvastatin plus Trimetazidine in Percutaneous Coronary Intervention
por: Lin, Xuefeng, et al.
Publicado: (2013)

Atorvastatin and prevention of contrast induced nephropathy following coronary angiography
por: Bidram, Peyman, et al.
Publicado: (2015)

Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters
por: Lee, Cheol Hyun, et al.
Publicado: (2022)

Stress Degradation Behavior of Atorvastatin Calcium and Development of a Suitable Stability-Indicating LC Method for the Determination of Atorvastatin, its Related Impurities, and its Degradation Products
por: Vukkum, Pallavi, et al.
Publicado: (2013)

Attention training technique delivered in groups as treatment for anxiety and depression in patients with coronary heart disease: study protocol for a waiting-list randomized controlled trial
por: Dammen, Toril, et al.
Publicado: (2023)

Symptom burden and job absenteeism after treatment with additional catheter-directed thrombolysis for deep vein thrombosis
por: Enden, Tone, et al.
Publicado: (2013)

The effects of atorvastatin therapy on endothelıal function in patients with coronary artery disease
por: Yildiz, Ahmet, et al.
Publicado: (2007)

Biodegradable Polymers Influence the Effect of Atorvastatin on Human Coronary Artery Cells
por: Strohbach, Anne, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5007uovjg5jqo3hqq7f214nf30